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ABSTRACT
Pharmacological targeting of BTK using ibrutinib has recently shown encouraging 
clinical activity in a range of lymphoid malignancies. Recently we reported that 
ibrutinib inhibits human acute myeloid leukemia (AML) blast proliferation and 
leukemic cell adhesion to the surrounding bone marrow stroma cells. Here we report 
that in human AML ibrutinib, in addition, functions to inhibit SDF1/CXCR4-mediated 
AML migration at concentrations achievable in vivo.  It has previously been shown 
that SDF1/CXCR4-induced migration is dependent on activation of downstream BTK 
in chronic lymphocytic leukaemia (CLL) and multiple myeloma. Here we show that 
SDF-1 induces BTK phosphorylation and downstream MAPK signalling in primary AML 
blast. Furthermore, we show that ibrutinib can inhibit SDF1-induced AKT and MAPK 
activation. These results reported here provide a molecular mechanistic rationale for 
clinically evaluating BTK inhibition in AML patients and suggests that in some AML 
patients the blasts count may initially rise in response to ibrutinib therapy, analgous 
to similar clinical observations in CLL.
INTRODUCTION
Despite recent significant progress in the 
understanding of the biology of AML the clinical 
outcomes for the majority of patients diagnosed with AML 
presently remain poor. AML is primarily a disease of the 
elderly[1], and for most of the 75% of patients aged over 
60 at diagnosis long term survival has barely improved in 
the last 40 years [2], largely because the intensity and side 
effects of existing curative therapeutic strategies (which 
are commonly used to treat the younger fitter patients) 
coupled to patient co-morbidities, frequently limit their 
use in this older less fit population. Consequently, there 
is an urgent need to identify pharmacological strategies in 
AML, which are not only effective but can be tolerated by 
the older, less well patient. It is envisaged that treatments 
which target tumor-specific biology will help realise this 
goal.
Bruton’s Tyrosine Kinase (BTK) is a non-
receptor tyrosine kinase that belongs to the Tec family 
and clearly has an important function in a number 
of benign and malignant cells of the haematopoietic 
system [3-7]. Moreover, recent phase 1, 2 and 3 studies 
of the irreversible oral BTK inhibitor, ibrutinib have 
demonstrated excellent clinical activity and tolerability 
against a variety of B-cell malignancies including, chronic 
lymphocytic leukemia (CLL), mantle cell lymphoma, 
hairy cell leukaemia and diffuse large B-cell lymphoma 
in younger and older patients alike [8-16]. Furthermore, 
it is now clear that the mechanism of action [MOA] of 
ibrutinib is multifactorial in nature with a significant 
component of its function in lymphoid malignancy 
involving disruption of the interaction between the tumor 
cell and the microenvironment that protects it. Recently 
our group and others have shown that there is high BTK 
phosphorylation and RNA expression in AML [17-19]. 
Moreover, our recent study described for the first time 
that ibrutinib and BTK-targeted RNA interference reduced 
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factor-induced proliferation of both AML cell lines and 
primary AML blasts, as well as reducing AML blast 
adhesion to BMSC [19]. 
Inhibition of BTK has been shown to regulate 
CLL, MCL and MM cell migration by inhibiting SDF1 
(stromal derived factor 1) induced CXCR4 regulated cell 
trafficking [20-22]. SDF1 is an extracellular chemokine 
which is abundantly produced by the bone marrow 
microenvironment binds to and activates its receptor 
CXCR4 which is highly expressed on many non-malignant 
and malignant cells including breast cancer cell, normal 
haematopoietic CD34+ cells as well as AML blasts [23, 
24]. In this study we investigate the role of BTK inhibition 
on the function of SDF-1/CXCR4 in AML. Furthermore, 
we examine the intracellular signalling cascade down 
stream of SDF1/CXCR4 activation, specifically the effects 
on AKT and MAPK. Finally, we examine the role of BTK 
RNAi on SDF-1/CXCR4-mediated AML migration. 
RESULTS
Ibrutinib inhibits AML cell migration in response 
to SDF-1
Previously we have shown that ibrutinib inhibits 
AML proliferation and adhesion to BMSC. In myeloma 
and CLL ibrutinib inhibits CXCR4/SDF1-mediated 
migration [11, 25]. Moreover, inhibition of CXCR4/SDF1 
axis using AMD3100 (Plerixafor), an agonist for CXCR4, 
has been shown to decrease AML tumor burden in AML 
leukaemic mice in combination with conventional AML 
chemotherapy [26]. Therefore we initially examined the 
expression of CXCR4 in human AML cell lines and found 
that 4/4 cell lines were positive for CXCR4 expression 
(Figure 1A). Next we examined the effects of ibrutinib on 
the migration of the AML cell lines U937, MV4-11, HL60 
and THP-1 in response to SDF1. Figure 1B shows that 
ibrutinib can inhibit the migration of all AML cell lines 
tested. Finally, we tested the in-vitro activity of ibrutinib 
on SDF-1 induced migration in a spectrum of primary 
AML blasts from a wide age spectrum of adult patients 
and across a range of WHO AML subclasses (Table 1). 
Figure 1C shows that ibrutinib significantly inhibits 
primary AML blast migration (n=12). Taken together these 
data show that ibrutinib inhibits SDF1/CXCR4 driven 
migration in human AML. 
BTK is activated in response to SDF-1 in human 
AML
Since SDF1 has been shown to mediate migration 
of AML in a CXCR4 dependent mechanism and that 
SDF1/CXCR4-induced migration is dependent on 
activation of downstream BTK in CLL, myeloma and 
normal B cells [21, 27], we examined the activity of BTK 
phosphorylation and downstream AKT and MAPK in 
response to SDF1 and found that SDF1 increases levels 
of pBTK and downstream MAPK in primary AML blasts 
(Figure 2A). Since CXCR4 activation has been shown to 
mediate downstream MAPK and AKT activity [28, 29], we 
examined if ibrutinib could inhibit SDF1 induced MAPK 
and AKT signalling in primary AML blast. Figure 2B 
shows that ibrutinib inhibits SDF1 induced BTK, MAPK 
and AKT phosphorylation in AML at concentrations 
equivalent to those that can be achieved in vivo (based on 
ibrutinib 420 mg orally once a day) [10, 16]. These results 
demonstrate that ibrutinib inhibits CXCR4 mediated 
signalling in primary human AML cells.
Pharmacological inhibition of G proteins inhibits 
SDF1 induced BTK activation
Since CXCR4 is a Gi-coupled receptor and pertussis 
toxin inhibits Gi-coupled receptor activation [30], 
we used pertussis toxin to determine if SDF1 induces 
phosphorylation of BTK through CXCR4. To do this we 
treated AML cell line MV4-11 with pertussis toxin for 
15 mins before the addition of SDF1 for 10mins. Figure 
3A shows that pertussis toxin can inhibit SDF1 mediated 
phospoBTK activation in AML blasts. Next we wanted to 
determine if inhibition of CXCR4 activation by pertussis 
toxin as well as inhibition of downstream AKT and MAPK 
, could also block SDF1 induced migration of AML cell 
line MV4-11. Figure 3B shows that pertussis toxin, 
PD98059 and AKT inhibitor VIII could all inhibit SDF1 
induced migration in MV4-11 cells. 
Knockdown of BTK inhibits SDF1 induced 
migration in AML
It has been shown that ibrutinib has multiple kinase 
targets including interleukin-2-inducible kinase [31], 
as well as other members of the TEC kinase family. 
Therefore to eliminate the problems associated with 
off target inhibitor activity we evaluated migration of 
AML cells lines using genetic inhibition of BTK. To do 
this we generated lentivirus-mediated long-term BTK 
knockdown using targeted artificial microRNA (BTK-
targeted miRNA) and visualisation of infected cells by 
a concurrently expressed GFP signal tag as previously 
described [19]. The introduction of BTK-specific miRNA 
dramatically inhibited the expression of BTK in THP-1 
and HL60 (Figure 4A). Next we examined the role of 
mRNA targeted BTK knockdown on THP-1 and HL60 
migration. Figure 4B shows that AML cells with BTK-
KD had reduced SDF1 mediated migration confirming 
that BTK is involved in regulating AML migration in 
response to SDF1. Figure 4C shows a schematic of how 
BTK targets SDF1/CXCR4 signalling in AML.
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Figure 1: Ibrutinib inhibits AML cell migration in response to SDF-1 (A). AML cell lines were examined for CXCR4 
expression (n=4) using flow cytometry (B) AML cell lines were pretreated with 500nM of ibrutinib for 1 h before wash off and then placed 
in the upper well of a 8.0µM transwell plate. The lower chamber contained 500ul of serum free media supplemented with SDF1 (100 ng/ml) 
for 3 hours and then assessed for cell number using a flow cytometer. Data were normalised to DMSO treated cells. *statistical significance. 
(C) Primary AML blasts (n=12) were pretreated with ibrutinib (500 nM) for 1 h before wash off and then placed in the upper well of a 
8.0µM transwell plate. The lower chamber contained 500ul of serum free media supplemented with SDF1 (100 ng/ml) for 3 hours and then 
assessed for cell number using a flow cytometer. Data were normalised to DMSO treated cells. 
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Table 1: AML patient sample information. This table defines the nature of the AML disease 
including WHO diagnosis and cytogenetics. 
Figure 2: BTK is activated in response to SDF-1 in human AML. (A) AML blasts were treated with SDF1 (100 ng/ml) for 
indicated times. Protein extracts were obtained and Western blot analysis was conducted for pBTK, BTK, pMAPK, MAPK and β-actin 
protein levels. (B) AML blasts were pretreated with increasing concentrations of ibrutinib for 1h and then treated with SDF1 (100 ng/ml) 
for 10 mins. Protein extracts were obtained and Western blot analysis was conducted for pATK, ATK, pMAPK, MAPK and β-actin protein 
levels. These results are representative of experiments which were repeated three times with the bar graphs showing mean expression (as 
measured by densitometry) compared to control from all 3 experiments.
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Figure 3: Pharmacological inhibition of G-proteins, AKT and ERK block SDF1 induced migration in AML. (A) MV4-11 
cells were pretreated with pertussis toxin (100ng/ml) for 30 mins and then stimulated with SDF1 for 10mins. Protein extracts were obtained 
and Western blot analysis was conducted for pBTK, BTK and β-actin protein levels. These results are representative of experiments which 
were repeated three times. (B) MV4-11 cells were pretreated with pertussis toxin (100ng/ml), PD98059 (20 μM) and AKT inhibitor VIII 
(2 μM) for 30 mins and then placed in the upper well of a 8.0µM transwell plate. The lower chamber contained 500ul of serum free media 
supplemented with SDF1 (100 ng/ml) for 3 hours and then assessed for cell number using a flow cytometer. Data were normalised to DMSO 
treated cells. *statistical significance compared to SDF1 MV4-11 cells. 
Figure 4: Knockdown of BTK inhibits SDF1 induced migration in AML. (A) AML cell lines (HL60 and THP-1) were 
transduced with BTK-targeted miRNA (BTK-KD) or a negative-targeted miRNA (NEG-KD) GFP-tagged lentiviral constructs for 72 h. 
Protein extracts were obtained and Western blot analysis was conducted for BTK and β-actin protein levels. These results are representative 
of experiments which were repeated three times (B) HL60 and THP-1 were transduced with BTK-KD and NEG-KD lentivirus for 72 h 
and then placed in the upper well of a 8.0µM transwell plate. The lower chamber contained 500ul of serum free media supplemented with 
SDF1 (100 ng/ml) for 3 hours and then assessed for cell number using a flow cytometer. Data were normalised to NEG-KD cells. *statistical 
significance. (C) Schematic to show the role of BTK inhibition by ibrutinib in preventing AML migration.
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DISCUSSION
BTK is a cytoplasmic tyrosine kinase widely 
expressed in hematopoietic cells and long known to be 
critical in B cell differentiation and survival pathways. 
BTK is a member of the BTK/Tec family of tyrosine 
kinases [32]. BTK activation has been implicated in a 
variety of hematopoietic cellular responses and there is 
a growing literature supporting the role of BTK in HSC 
and cells of the myeloid compartment [33-35]. Previously 
we have shown that ibrutinib inhibits AML adhesion to 
BMSC. In the present study we develop on these findings 
to investigate the effect of BTK inhibition using ibrutinib 
on AML blast migration.
In CLL and other B cell malignancies ibrutinib 
inhibits SDF1/CXCR4-induced tumor cell migration 
[20, 25]. We hypothesised that SDF1/CXCR4 signalling 
was also regulated by BTK in AML. Inhibition of 
CXCR4 signalling using the CXCR4 inhibitor AMD3100 
(Plerixafor) can mobilise non-malignant hematopoietic 
stem cells from the bone marrow in to the peripheral 
blood for harvesting[36]. Moreover, in AML AMD3100 
has been shown to increase the level of AML cells in the 
peripheral blood and therefore increase their sensitivity to 
chemotherapy in murine models [26]. Our data confirm 
that ibrutinib targets SDF1/CXCR4 signalling. 
Ibrutinib has been shown to be well tolerated 
with limited grade 3 and 4 toxicity across a broad age 
range of patients with CLL and MCL [5, 15, 16] . Since 
AMD3100 inhibits SDF1-mediated non-malignant CD34+ 
cell migration we also expect ibrutinib to do the same, 
however, as we have observed previously we expect 
ibrutinib to inhibit pro-survival signals including SCF 
mediated and to a lesser extent IL-3 and GM-CSF in AML 
[19]. The clinical significance of the ibrutinib effect on 
non-malignant HSC in patients with AML can only be 
defined in the context of clinical trials. 
In patients with CLL treated with ibrutinib an 
initial and sometimes persistent rise in the circulating 
lymphocyte count may be seen, even in the context of 
clinically responding disease [8]. This is believed to occur 
in part because of an egress of malignant cells from nodal 
compartments[37]. In AML blocking of SDF/CXCR4 by 
AMD3100 is associated with a rise in circulating tumour 
cells[26]. In light of these reports and our own findings 
that Ibrutinib inhibits CXCR4/SDF1 mediated migration 
in AML we hypothesise that in some AML patients the 
blast count may initially rise in response to ibrutinib 
therapy. However while the rising lymphocyte count in 
CLL causes no known harm to the patient, an uncontrolled 
rise in the blast count in AML may put patients at risk 
of leucostasis. Accordingly we suggest future clinical 
trial protocols of BTK inhibition in human AML should 
include strategies to manage a rising blast count (such as 
addition of cytoreductive chemotherapy) should it occur.
Here we show for the first time that in human AML 
ibrutinib inhibits SDF1/CXCR4 pathway and functions 
to disrupt migration signals from the microenvironment 
This study further validates an emerging focus of targeting 
kinases critical for the survival of malignant cells and 
gives us a clearer understanding of how inhibition of BTK 
may optimally be harnessed therapeutically in AML. In 
summary, we provide additional scientific support for 
clinical trials of ibrutinib in patients with AML. 
METHODS
Materials
Anti-phosphorylated and pan AKT, BTK and 
MAPK antibodies were purchased from Cell Signaling 
Technology (Cambridge, MA). Anti-CD34-PE and anti-
CXCR4-FITC antibodies were purchased from Miltenyi 
Biotec (Auburn, CA). Ibrutinib was obtained from 
Selleck Chemicals. SDF1 was purchased from Miltenyi 
Biotec. Pertusis toxin was purchased from R&D systems 
(Abingdon, UK). LY294002 and U0126 were purchased 
from Cell Signalling Technology. All other reagents were 
obtained from Sigma-Aldrich (St Louis, MO), unless 
indicated.
Cell culture 
AML cells were obtained from patients’ bone 
marrow or blood following informed consent and under 
approval from the UK National Research Ethics Service 
(LRECref07/H0310/146). For primary cell isolation, 
heparinized blood was collected from volunteers and 
human peripheral blood mononuclear cells (PBMCs) 
isolated by Histopaque (Sigma-Aldrich, UK) density 
gradient centrifugation. AML samples that were less than 
80% blasts were purified using the CD34 positive selection 
kit (denoted by * in Table 1). Cell type was confirmed by 
microscopy and flow cytometry as previously described 
[38]. 
The AML-derived cell lines were obtained from 
the DMSZ (German Collection of Microorganisms and 
Cell Cultures) and European Collection of Cell Cultures 
where they are authenticated by DNA-fingerprinting. In 
the laboratory they are used at low passage number for a 
maximum of 6 months post-resuscitation, testing regularly 
for Mycoplasma infection 
Virus construction and infection
MicroRNA sequence miRNA-BTK 
(5’-TTCACTGGACTCTTCACCTCT-3’) targeting 
human BTK was selected with Invitrogen Block-iT RNAi 
Designer software (www.invitrogen.com/rnai) and plasmid 
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pcDNATM6.2-GW/EmGFP-miR-neg (Invitrogen) was 
used as source for negative control as previously described 
[19] [38]. 
Western immunoblotting
Sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis and Western blot analyses were performed 
as described previously. Briefly, whole cell lysates as 
well as nuclear and cytosolic were extracted and sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis 
separation performed [39, 40]. Protein was transferred 
on nitrocellulose membrane and Western blot analysis 
performed with the indicated antisera according to their 
manufacturer’s guidelines
Migration Assays
Migration assays were performed in triplicate in 
Transwell permeable plates with 8.0µM pores (Costar). 
The lower compartment contained 500µL of serum free 
media supplemented with 100 ng/ml SDF1 and the cells 
were applied to the upper compartment and allowed to 
migrate for 3 h. The amount of viable migrated cells was 
determined by counting using trypan blue exclusion and 
expressed as a percentage of the input. The bars represent 
the means ± SD of at least three independent experiments, 
each assayed in triplicate.
Statistical analyses
Student’s T test was performed to assess statistical 
significance from controls. Results with P < 0.05 were 
considered statistically significant (*). Results represent 
the mean ± SD of 3 independent experiments. For Western 
blotting, data are representative images of 3 independent 
experiments.
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